Would you use Ibrutinib plus Venetoclax as second line therapy in relapsed/refractory mantle cell lymphoma?

I may consider this for the right patient with Mantle cell lymphoma that has relapsed with TP53 and high risk prognostic score. Even though the data is very exciting it is a single arm study with a small patient cohort, I would want to see a randomized data to make a definitive switch. The CR rates ...

Thank you for your quick answer. The data, although a small non-randomized sample, does look exciting. Such high and durable responses in a disease where there aren't many good refractory treatments. It is also interesting to note that only 17% of the patients had Bendamustine in their prior regimen...